Drug Shortage Report for CAELYX
| Report ID | 229782 |
| Drug Identification Number | 02238389 |
| Brand name | CAELYX |
| Common or Proper name | Liposomal Doxorubicin |
| Company Name | BAXTER CORPORATION |
| Market Status | MARKETED |
| Active Ingredient(s) | DOXORUBICIN HYDROCHLORIDE |
| Strength(s) | 2MG |
| Dosage form(s) | SUSPENSION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
|
Packaging sizes (GTIN)
Click here to see a list of all reports for this drug. |
(See additional packaging sizes) |
| Additional packaging sizes | BX411008 CAELYX (Liposomal Doxorubicin), 20mg / 10mL vial |
| ATC code | L01DB |
| ATC description | CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES |
| Reason for shortage | Delay in shipping of the drug. |
| Anticipated start date | 2024-08-01 |
| Actual start date | 2024-08-08 |
| Estimated end date | 2024-08-31 |
| Actual end date | 2024-08-29 |
| Shortage status | Resolved |
| Updated date | 2024-08-30 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 7125 MISSISSAUGA ROAD MISSISSAUGA, ONTARIO CANADA L5N 0C2 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v8 | 2024-08-30 | English | Compare |
| v7 | 2024-08-29 | French | Compare |
| v6 | 2024-08-29 | English | Compare |
| v5 | 2024-08-09 | English | Compare |
| v4 | 2024-08-01 | French | Compare |
| v3 | 2024-08-01 | English | Compare |
| v2 | 2024-06-06 | French | Compare |
| v1 | 2024-06-06 | English | Compare |
Showing 1 to 8 of 8